期刊
METABOLISM-CLINICAL AND EXPERIMENTAL
卷 83, 期 -, 页码 159-166出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2017.10.014
关键词
GLP-1; Bariatric surgery; Exendin-9; Glucose; Diabetes; Obesity
资金
- National Institutes of Health [DK083554-05, DK105379]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK105379] Funding Source: NIH RePORTER
Bariatric surgery is an effective treatment for obesity. The two widely performed weight-loss procedures, Roux en-Y gastric bypass (GB) and sleeve gastrectomy (SG). alter postprandial glucose pattern and enhance gut hormone secretion immediately after surgery before significant weight loss. This weight-loss independent glycemic effects of GB has been attributed to an accelerated nutrient transit from stomach pouch to the gut and enhanced secretion of insulinotropic gut factors; in particular, glucagon-like peptide-1 (GLP-1). Meal-induced GLP-1 secretion is as much as tenfold higher in patients after GB compared to non-surgical individuals and inhibition of GLP-1 action during meals reduces postprandial hyperinsulinemia after GB two to three times more than that in persons without surgery. Moreover, in a subgroup of patients with the late complication of postprandial hyperinsulinemic hypoglycemia after GB, GLP1R blockade reverses hypoglycemia by reducing meal stimulated insulin secretion. The role of enteroinsular axis activity after SG, an increasingly popular alternative to GB, is less understood but, similar to GB, SG accelerates nutrient delivery to the intestine, improves glucose tolerance, and increases postprandial GLP-1 secretion. This review will focus on the current evidence for and against the role of GLP-1 on glycemic effects of GB and will also highlight differences between GB and SG. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据